Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Greenhalf, William ^a   Ghaneh, Paula ^a   Neoptolemos, John P ^a   Palmer, Daniel H ^d   Cox, Trevor F ^a   Lamb, Richard F ^m   Garner, Elizabeth ^a   Campbell, Fiona ^a   MacKey, John R ^p   Costello, Eithne ^a   Moore, Malcolm J ^b   Valle, Juan W ^c   McDonald, Alexander C ^e   Carter, Ross ^f,g   Tebbutt, Niall C ^h   Goldstein, David ⁱ   Shannon, Jennifer ^j   Dervenis, Christos ^k   Glimelius, Bengt ^l   Deakin, Mark ⁿ   Charnley, Richard M ^o   Lacaine, François ^g   Scarfe, Andrew G ^p   Middleton, Mark R ^q   Anthoney, Alan ^r   Halloran, Christopher M ^a   Mayerle, Julia ^s   Oláh, Attila ^t   Jackson, Richard ^a   Rawcliffe, Charlotte L ^a   Scarpa, Aldo ^u   Bassi, Claudio ^u   Büchler, Markus W ^v   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

^g HÔPITAL TENON   (France)

^h AUSTIN HEALTH   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

^k AGIA OLGA HOSPITAL   (Greece)

^l CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^m UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁿ University Hospital   (United Kingdom)

^o FREEMAN HOSPITAL   (United Kingdom)

^p UNIVERSITY OF ALBERTA   (Canada)

^q CHURCHILL HOSPITAL   (United Kingdom)

^r ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^s UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^t Petz Aladár Hospital   (Hungary)

^u UNIVERSITY OF VERONA   (Italy)

^v UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; SLC29A1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; ADENOCARCINOMA; AGED; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; EUROPE; METABOLISM; MORTALITY; MULTICENTER STUDY; PANCREAS TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EUROPE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84892633020     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt347     Document Type: Article

References (34)

1. Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012;148(1-2):21-23.
2. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012;10(6):703-713.
3. Van Laethem JL, Verslype C, Iovanna JL, et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol. 2012;23(3):570-576.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
5. Von Hoff DD et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol. 2013;13(Suppl): abstract 4005.
6. Neoptolemos JP, Dunn JA, Moffitt DD, et al. ESPAC-1: a European, randomized controlled study of adjuvant chemoradiation and chemotherapy in resectable pancreatic cancer. Lancet. 2001;358(9293):1576-1585.
7. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
8. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277.
9. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-1081.
10. Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer.J Clin Oncol. 2013;31(Suppl): abstract 4008.
11. Stocken D, Büchler M, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92(8):1372-1381.
12. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019-1026.
13. Twombly R. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst. 2008;100(23):1670-1671.
14. Li D, Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res. 2010;16(17):4313-4318.
15. Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9(8):435-444.
16. Yao SY, Ng AM, Cass CE, et al. Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem. 2011;286(37):32552-32562.
17. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10(20):6956-6961.
18. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66(7):3928-3935.
19. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136(1):187-195.
20. Kim R, Tan A, Lai KK, et al. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 2011;117(14):3126-3134.
21. Maréchal R, Bachet JB, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 2012;143(3):664-674.
22. Fisher SB, Patel SH, Bagci P, et al. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment. Cancer. 2013;119(2):445-453.
23. Nakagawa N, Murakami Y, Uemura K, et al. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery. 2013;153(4):565-575.
24. Murata Y, Hamada T, Kishiwada M, et al. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabinebased chemoradiotherapy. J Hepatobiliary Pancreat Sci. 2012;19(4):413-425.
25. Kawada N, Uehara H, Katayama K, et al. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J Hepatobiliary Pancreat Sci. 2012;19(6):717-722.
26. Sarzotti-Kelsoe M, Cox J, Cleland N, et al.: Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. PLoS Med. 2009;6(5):e1000067.
27. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184.
28. Jennings LL, Hao C, Cabrita MA, et al. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology. 2001;40(5):722-731.
29. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Amer Stat Assoc. 1958;49(268):457-481.
30. Zhang J, Visser F, King KM, et al. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 2007;26:85-110.
31. Ward JL, Sherali A, Mo ZP, et al. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem. 2000;275(12):8375-8381.
32. Kobayashi Y, Ohshiro N, Sakai R, et al. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005;57(5):573-578.
33. Young JD, Yao SY, Sun L, et al. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica. 2008;38(7-8):995-1021.
34. Poplin E, Wasan H, Rolfe L, et al. Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment. J Clin Oncol. 2013;13(Suppl):abstract 4007.